Burning Rock Biotech Past Earnings Performance
Past criteria checks 0/6
Burning Rock Biotech's earnings have been declining at an average annual rate of -22.5%, while the Biotechs industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 14.1% per year.
Key information
-22.5%
Earnings growth rate
11.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 14.1% |
Return on equity | -85.1% |
Net Margin | -121.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?
Mar 25There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues
Feb 01Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jul 12Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?
Apr 28We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully
Dec 23Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?
Sep 20Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M
Aug 31Burning Rock Localizes As Investors Grow Impatient
Jun 06We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely
Mar 24Following Rough Year, Is Burning Rock Set To Turn The Corner?
Nov 17Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?
Aug 27A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)
Jul 23Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?
May 13Burning Rock Biotech Expands Test Portfolio In Bid For Growth
Dec 30Burning Rock inks license pact with Oncocyte Corporation
Dec 15Burning Rock Biotech prices upsized offering of 2.243M ADSs at $25.75/ADS
Dec 04Burning Rock Biotech EPS misses by $0.08, beats on revenue
Nov 20Revenue & Expenses BreakdownBeta
How Burning Rock Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 537 | -654 | 686 | 347 |
30 Sep 23 | 559 | -708 | 735 | 372 |
30 Jun 23 | 586 | -764 | 788 | 397 |
31 Mar 23 | 570 | -895 | 903 | 394 |
31 Dec 22 | 563 | -971 | 939 | 422 |
30 Sep 22 | 568 | -1,006 | 965 | 434 |
30 Jun 22 | 540 | -945 | 925 | 394 |
31 Mar 22 | 537 | -887 | 853 | 410 |
31 Dec 21 | 508 | -797 | 793 | 368 |
30 Sep 21 | 492 | -702 | 720 | 339 |
30 Jun 21 | 490 | -659 | 674 | 338 |
31 Mar 21 | 469 | -564 | 570 | 301 |
31 Dec 20 | 430 | -472 | 462 | 264 |
30 Sep 20 | 387 | -450 | 390 | 233 |
30 Jun 20 | 367 | -389 | 316 | 202 |
31 Mar 20 | 345 | -347 | 291 | 166 |
31 Dec 19 | 382 | -334 | 285 | 157 |
30 Sep 19 | 358 | -268 | 248 | 137 |
31 Dec 18 | 209 | -232 | 191 | 105 |
31 Dec 17 | 111 | -185 | 144 | 49 |
Quality Earnings: BNR is currently unprofitable.
Growing Profit Margin: BNR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BNR is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare BNR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BNR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: BNR has a negative Return on Equity (-85.07%), as it is currently unprofitable.